Healthcare
Live Price
Offline$5.46
+4.20% today
1Y Change
+60.00%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
SOPHiA GENETICS S.A. (SOPH) is a Healthcare stock with a market cap of $380.00M and listed on NASDAQ. The stock last traded around $5.46 and up 60.0% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +18.6%, EPS growth of -23.2%, a dividend yield of 0.0%. What stands out right now is revenue +18.6%, EPS -23.2%, free cash flow +24.3% with operating margin -91.2% and ROIC -61.0%. Valuation sits in the middle of the pack at price/sales 4.9. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines SOPH price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
SOPH
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
SOPH Max Drawdown
-25.72%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for SOPH and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$40.5M
-14.9% YoY
FY Net Income
-$73.7M
+15.8% YoY
Free Cash Flow
-$64.6M
+19.7% YoY
Revenue Growth
+18.6%
EPS Growth
-23.2%
Gross Margin
67.4%
Net Margin
-102.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 77M | 65M | 62M | 48M | 40M |
| Gross Profit | 48M | 44M | 43M | 31M | 25M |
| Operating Income | -71M | -67M | -75M | -88M | -71M |
| EBITDA | -61M | -51M | -70M | -81M | -69M |
| Net Income | -79M | -62M | -79M | -87M | -74M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 70M | 80M | 123M | 161M | 193M |
| Total Assets | 163M | 155M | 206M | 244M | 320M |
| Total Liabilities | 116M | 59M | 55M | 44M | 45M |
| Shareholder Equity | 47M | 96M | 151M | 200M | 275M |
| Total Debt | 63M | 30M | 19M | 17M | 13M |
| Net Debt | -7M | -50M | -105M | -145M | -180M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
58M
+17.3% YoY
Capital Expenditures
7M
+35.7% YoY
Free Cash Flow
65M
+19.7% YoY
Key ratios
Gross Margin
67.4%
Operating Margin
-91.2%
Net Margin
-102.2%
ROE
-117.0%
Debt / Equity
1.34x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.